RT Journal Article
T1 I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation
A1 Tamargo Menéndez, Juan
A1 Caballero Collado, Ricardo
A1 Gómez García, Ricardo
A1 Delpón Mosquera, María Eva
AB Atrial fibrillation (AF) is the most common sustained arrhythmia. Anti-arrhythmic drugs remain the mainstay of therapy, but the available class I and III anti-arrhythmic drugs are only moderately effective in long-term restoring/maintaining sinus rhythm (SR) and can produce potentially fatal ventricular pro-arrhythmia. In an attempt to identify safer and more effective anti-arrhythmic drugs, drug discovery efforts have focused on 'atrial selective drugs' that target cardiac ion channel(s) that are exclusively or predominantly expressed in the atria. The ultra-rapid activating delayed rectifier K(+) current (I(Kur)), carried by Kv1.5 channels, is a major repolarizing current in human atria, but seems to play no role in the ventricle. This finding offers the possibility of developing selective I(Kur) blockers to restore and maintain SR without a risk of ventricular pro-arrhythmia. Several I(Kur) blockers are now being developed but clinical data are still limited, so the precise role of these agents in the treatment of AF remains to be defined. In this review we analyze the possible advantages and disadvantages of the developmental I(Kur) blockers as they represent the first step for the development of potential atrial selective drugs for a more effective and safer treatment and prevention of AF.
PB Taylor & Francis 
SN 1354-3784
YR 2009
FD 2009
LK https://hdl.handle.net/20.500.14352/93022
UL https://hdl.handle.net/20.500.14352/93022
LA eng
NO Tamargo J, Caballero R, Gómez R, Delpón E. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs. 2009 Apr;18(4):399-416. doi: 10.1517/13543780902762850
NO Comisión Interministerial de Ciencia y Tecnología (España)
NO European Commission
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 6 abr 2025